We previously revealed that the treatment of cervical cancer cells with LMB, an exportin-1 inhibitor, prevents the nuclear export of HP1γ, and thus, suppresses the expression of UBE2L3 while promoting p53 signaling [15]. This evidence concerns the gene TP53 and cervical cancer.